List of Excipients in API sitagliptin
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing sitagliptin
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | JANUVIA | sitagliptin | 0006-0221 | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | |
| Merck Sharp & Dohme LLC | JANUVIA | sitagliptin | 0006-0221 | CELLULOSE, MICROCRYSTALLINE | |
| Merck Sharp & Dohme LLC | JANUVIA | sitagliptin | 0006-0221 | CROSCARMELLOSE SODIUM | |
| Merck Sharp & Dohme LLC | JANUVIA | sitagliptin | 0006-0221 | FERRIC OXIDE RED | |
| Merck Sharp & Dohme LLC | JANUVIA | sitagliptin | 0006-0221 | FERRIC OXIDE YELLOW | |
| Merck Sharp & Dohme LLC | JANUVIA | sitagliptin | 0006-0221 | MAGNESIUM STEARATE | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for sitagliptin
Excipient focus: ALUMINUM OXIDE
sitagliptin drug variants containing ALUMINUM OXIDE
sitagliptin drug variants not containing ALUMINUM OXIDE
Excipient focus: ANHYDROUS CITRIC ACID
sitagliptin drug variants containing ANHYDROUS CITRIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Azurity Pharmaceuticals Inc | sitagliptin hydrochloride oral | 24338-017 |
| >Company | >Ingredient | >NDC |
sitagliptin drug variants not containing ANHYDROUS CITRIC ACID
Excipient focus: ANHYDROUS DIBASIC CALCIUM PHOSPHATE
sitagliptin drug variants containing ANHYDROUS DIBASIC CALCIUM PHOSPHATE
sitagliptin drug variants not containing ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Excipient focus: BUTYLATED HYDROXYANISOLE
sitagliptin drug variants containing BUTYLATED HYDROXYANISOLE
| Company | Ingredient | NDC |
|---|---|---|
| Azurity Pharmaceuticals Inc | sitagliptin hydrochloride oral | 24338-017 |
| >Company | >Ingredient | >NDC |
sitagliptin drug variants not containing BUTYLATED HYDROXYANISOLE
Excipient focus: CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
sitagliptin drug variants containing CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
| Company | Ingredient | NDC |
|---|---|---|
| Clinical Solutions Wholesale | sitagliptin | 58118-0277 |
| >Company | >Ingredient | >NDC |
sitagliptin drug variants not containing CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
Excipient focus: CARNAUBA WAX
sitagliptin drug variants containing CARNAUBA WAX
sitagliptin drug variants not containing CARNAUBA WAX
Excipient focus: CELLULOSE, MICROCRYSTALLINE
sitagliptin drug variants containing CELLULOSE, MICROCRYSTALLINE
sitagliptin drug variants not containing CELLULOSE, MICROCRYSTALLINE
Excipient focus: CROSCARMELLOSE SODIUM
sitagliptin drug variants containing CROSCARMELLOSE SODIUM
sitagliptin drug variants not containing CROSCARMELLOSE SODIUM
Excipient focus: EDETATE DISODIUM
sitagliptin drug variants containing EDETATE DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Azurity Pharmaceuticals Inc | sitagliptin hydrochloride oral | 24338-017 |
| >Company | >Ingredient | >NDC |
sitagliptin drug variants not containing EDETATE DISODIUM
Excipient focus: FD&C BLUE NO. 2
sitagliptin drug variants containing FD&C BLUE NO. 2
sitagliptin drug variants not containing FD&C BLUE NO. 2
Excipient focus: FD&C YELLOW NO. 6
sitagliptin drug variants containing FD&C YELLOW NO. 6
sitagliptin drug variants not containing FD&C YELLOW NO. 6
Excipient focus: FERRIC OXIDE RED
sitagliptin drug variants containing FERRIC OXIDE RED
sitagliptin drug variants not containing FERRIC OXIDE RED
Excipient focus: FERRIC OXIDE YELLOW
sitagliptin drug variants containing FERRIC OXIDE YELLOW
sitagliptin drug variants not containing FERRIC OXIDE YELLOW
Excipient focus: FERROSOFERRIC OXIDE
sitagliptin drug variants containing FERROSOFERRIC OXIDE
sitagliptin drug variants not containing FERROSOFERRIC OXIDE
Excipient focus: HYDROXYETHYL CELLULOSE
sitagliptin drug variants containing HYDROXYETHYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Azurity Pharmaceuticals Inc | sitagliptin hydrochloride oral | 24338-017 |
| >Company | >Ingredient | >NDC |
sitagliptin drug variants not containing HYDROXYETHYL CELLULOSE
Excipient focus: HYDROXYPROPYL CELLULOSE
sitagliptin drug variants containing HYDROXYPROPYL CELLULOSE
sitagliptin drug variants not containing HYDROXYPROPYL CELLULOSE
Excipient focus: HYPROMELLOSE 2208
sitagliptin drug variants containing HYPROMELLOSE 2208
sitagliptin drug variants not containing HYPROMELLOSE 2208
Excipient focus: HYPROMELLOSE 2910
sitagliptin drug variants containing HYPROMELLOSE 2910
sitagliptin drug variants not containing HYPROMELLOSE 2910
Excipient focus: INDIGOTINDISULFONATE SODIUM
sitagliptin drug variants containing INDIGOTINDISULFONATE SODIUM
sitagliptin drug variants not containing INDIGOTINDISULFONATE SODIUM
Excipient focus: KAOLIN
sitagliptin drug variants containing KAOLIN
sitagliptin drug variants not containing KAOLIN
Excipient focus: LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
sitagliptin drug variants containing LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
sitagliptin drug variants not containing LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
Excipient focus: MAGNESIUM STEARATE
sitagliptin drug variants containing MAGNESIUM STEARATE
sitagliptin drug variants not containing MAGNESIUM STEARATE
Excipient focus: MALIC ACID
sitagliptin drug variants containing MALIC ACID
sitagliptin drug variants not containing MALIC ACID
Excipient focus: METHYLPARABEN SODIUM
sitagliptin drug variants containing METHYLPARABEN SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Azurity Pharmaceuticals Inc | sitagliptin hydrochloride oral | 24338-017 |
| >Company | >Ingredient | >NDC |
sitagliptin drug variants not containing METHYLPARABEN SODIUM
Excipient focus: POLYETHYLENE GLYCOL
sitagliptin drug variants containing POLYETHYLENE GLYCOL
sitagliptin drug variants not containing POLYETHYLENE GLYCOL
Excipient focus: POLYETHYLENE GLYCOL 3350
sitagliptin drug variants containing POLYETHYLENE GLYCOL 3350
sitagliptin drug variants not containing POLYETHYLENE GLYCOL 3350
Excipient focus: POLYETHYLENE GLYCOLS
sitagliptin drug variants containing POLYETHYLENE GLYCOLS
| Company | Ingredient | NDC |
|---|---|---|
| Clinical Solutions Wholesale | sitagliptin | 58118-0277 |
| >Company | >Ingredient | >NDC |
sitagliptin drug variants not containing POLYETHYLENE GLYCOLS
Excipient focus: POLYSORBATE 80
sitagliptin drug variants containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| Azurity Pharmaceuticals Inc | sitagliptin hydrochloride oral | 24338-017 |
| >Company | >Ingredient | >NDC |
sitagliptin drug variants not containing POLYSORBATE 80
Excipient focus: POLYVINYL ALCOHOL
sitagliptin drug variants containing POLYVINYL ALCOHOL
sitagliptin drug variants not containing POLYVINYL ALCOHOL
Excipient focus: POVIDONE
sitagliptin drug variants containing POVIDONE
sitagliptin drug variants not containing POVIDONE
Excipient focus: POVIDONE K30
sitagliptin drug variants containing POVIDONE K30
sitagliptin drug variants not containing POVIDONE K30
Excipient focus: PROPYL GALLATE
sitagliptin drug variants containing PROPYL GALLATE
sitagliptin drug variants not containing PROPYL GALLATE
Excipient focus: SILICON DIOXIDE
sitagliptin drug variants containing SILICON DIOXIDE
sitagliptin drug variants not containing SILICON DIOXIDE
Excipient focus: SODIUM CITRATE
sitagliptin drug variants containing SODIUM CITRATE
| Company | Ingredient | NDC |
|---|---|---|
| Azurity Pharmaceuticals Inc | sitagliptin hydrochloride oral | 24338-017 |
| >Company | >Ingredient | >NDC |
sitagliptin drug variants not containing SODIUM CITRATE
Excipient focus: SODIUM LAURYL SULFATE
sitagliptin drug variants containing SODIUM LAURYL SULFATE
sitagliptin drug variants not containing SODIUM LAURYL SULFATE
Excipient focus: SODIUM STEARYL FUMARATE
sitagliptin drug variants containing SODIUM STEARYL FUMARATE
sitagliptin drug variants not containing SODIUM STEARYL FUMARATE
Excipient focus: STARCH, CORN
sitagliptin drug variants containing STARCH, CORN
sitagliptin drug variants not containing STARCH, CORN
Excipient focus: TALC
sitagliptin drug variants containing TALC
sitagliptin drug variants not containing TALC
Excipient focus: TITANIUM DIOXIDE
sitagliptin drug variants containing TITANIUM DIOXIDE
sitagliptin drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Azurity Pharmaceuticals Inc | sitagliptin hydrochloride oral | 24338-017 |
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
sitagliptin drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| Azurity Pharmaceuticals Inc | sitagliptin hydrochloride oral | 24338-017 |
| >Company | >Ingredient | >NDC |
sitagliptin drug variants not containing WATER
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links